USPTO serial 97929646
HUMANIS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- CRUZADO, SAMANTHA LEE
- Law office
- TMO LAW OFFICE 128
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with HUMANIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Nazly Aileen Bayramoglu
Nazly Aileen Bayramoglu BAYRAMOGLU LAW OFFICES LLC1540 WEST WARM SPRINGS ROAD SUITE 100HENDERSON, NV 89014United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Systemic anti-infectives, namely, antiparasitic, antibacterial and antifungal pharmaceuticals; Musculo-skeletal system pharmaceutical products for the treatment of musculo-skeletal system diseases; Cardiovascular pharmaceuticals, namely, diuretics, lipid lowering agents, beta blocking agents, and calcium antagonists being calcium channel blockers; Pharmaceuticals for the prevention and treatment of disorders of the nervous system, namely, pharmaceuticals in the nature of analgesics, psychoanaleptics, and psycoleptics for the treatment of psychosis, anti-epileptics for the treatment of epilepsy, central nervous system drugs being drugs for the treatment of central nervous system disorders, anaesthetics, antiparkinson preparations for the treatment of parkinson's disease, namely, antiparkinson pharmaceuticals; Pharmaceuticals for the treatment of respiratory diseases and asthma; Pharmaceuticals for the treatment of hormonal disorders and the prevention of osteoporosis; Anti-diabetic pharmaceuticals; insulins; Pharmaceuticals for the treatment of Alimentary Tract and Metabolism; Pharmaceuticals for the treatment of bone diseases and joint diseases; Pharmaceuticals for the treatment of blood and blood forming organs; Pharmaceuticals for the treatment of viral and infectious diseases; Pharmaceuticals for use as antineoplastic agents, namely, pharmaceuticals for the treatment of cancer; Pharmaceuticals for the treatment of immune system related diseases and disorders; Pharmaceuticals for the treatment of sensory organs; Pharmaceuticals for the treatment of kidney diseases; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals for ophthalmological use | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 4, 2024 | MAB0 | ABANDONMENT NOTICE E-MAILED - INCOMPLETE RESPONSE | — |
| Sep 9, 2024 | ABN0 | ABANDONMENT - INCOMPLETE RESPONSE | — |
| Aug 29, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 29, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 29, 2024 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jun 7, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jun 7, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 7, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 9, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 9, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 9, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 9, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 9, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 9, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 5, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 8, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 13, 2023 | NWAP | NEW APPLICATION ENTERED | — |